Accelerating Genetic Medicine R&D Using Microfluidics
This review examines how microfluidics has been used in the formulation, preclinical, and clinical development of gene-delivery nanoparticles.
Microfluidics is fast becoming an essential tool for encapsulating nucleic acids. Microfluidics allows fine control over process parameters, enabling optimization of nanoparticle characteristics and nucleic acid encapsulation. The continuous, inherently scalable nature of the microfluidic process allows formulations to be optimized at low volumes, before being scaled-up using multiple microfluidic mixers in parallel. This review examines how microfluidics has been used in the formulation, preclinical, and clinical development of gene-delivery nanoparticles.
Download the
BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook.
Article Details
BioPharm International eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 36-39
Citation
When referring to this article, please cite it as S. Ip, D. Reichert, I. Captain, and R. J. Taylor, "Accelerating Genetic Medicine R&D Using Microfluidics," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
